- Report
- February 2024
- 70 Pages
Mexico
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Spain
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Iran
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Russia
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Australia
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
China
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Japan
From €4567EUR$4,750USD£3,918GBP
- Report
- February 2024
- 70 Pages
Japan
From €4567EUR$4,750USD£3,918GBP
- Report
- August 2023
- 70 Pages
Spain
From €4567EUR$4,750USD£3,918GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4567EUR$4,750USD£3,918GBP
- Report
- April 2023
- 115 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- October 2022
- 70 Pages
Africa
From €4567EUR$4,750USD£3,918GBP
- Report
- October 2019
- 125 Pages
Canada
From €4567EUR$4,750USD£3,918GBP
- Report
- March 2019
- 160 Pages
Middle East, Africa
From €4567EUR$4,750USD£3,918GBP
- Report
- January 2022
- 90 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- April 2023
- 110 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- October 2022
- 176 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- March 2019
- 90 Pages
Europe
From €4567EUR$4,750USD£3,918GBP
Insulin Glargine is a long-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. It is administered by subcutaneous injection and works by helping the body use glucose more efficiently. Insulin Glargine is a recombinant human insulin analog that is modified to reduce its solubility and prolong its action. It is available in both prefilled pens and vials.
Insulin Glargine is a key drug in the Endocrine and Metabolic Disorders Drugs market. It is used to treat diabetes, a chronic condition that affects millions of people worldwide. It is an important part of diabetes management, helping to control blood sugar levels and reduce the risk of complications.
Companies in the Insulin Glargine market include Sanofi, Eli Lilly, Novo Nordisk, Merck, and Boehringer Ingelheim. Show Less Read more